China Suzhou-based DiyaLab Biotech has completed its Series A strategic financing of nearly RMB 100 million ($13.6 million) led by Grand Yangtze Capital and followed by Shulan Junjie Capital, Zhangjiagang Jinmao Venture Capital, Zhangjiagang Talent No.1 Fund, and Zhangjiagang Wisdom Venture Capital.
The funds will be used for the research and development of laboratory tests for autoimmune and neurological diseases, production capacity expansion, and clinical trials.
Founded in 2016, DiyaLab is dedicated to the research and development of laboratory testing products for autoimmune and neurological diseases, with R&D centres in Shanghai and Zhangjiagang, Jiangsu Province. The company is one of the very few manufacturers in China that has mastered the core raw materials and core technologies of autoantibody and neurological marker laboratory testing products.
The Post is Available in: English – 简体中文
English (UK) 
简体中文 
Deutsch 
Français 
Español 
Português 
日本語 
Italiano 
Nederlands 
